Marc Sabatine

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials)
    Emmanouil S Brilakis
    Cardiovascular Division, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Am J Cardiol 102:552-8. 2008
  2. ncbi Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial
    Marc S Sabatine
    TIMI Study Group, Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Lancet 374:787-95. 2009
  3. ncbi Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Circulation 105:1760-3. 2002
  4. ncbi Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 35
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Eur Heart J 30:162-9. 2009
  5. ncbi Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial
    Marc S Sabatine
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Circulation 112:3846-54. 2005
  6. ncbi Something old, something new: beta blockers and clopidogrel in acute myocardial infarction
    Marc S Sabatine
    Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA
    Lancet 366:1587-9. 2005
  7. ncbi Novel antiplatelet strategies in acute coronary syndromes
    Marc S Sabatine
    Cardiovascular Medicine Division, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Cleve Clin J Med 76:S8-15. 2009
  8. ncbi Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 44:1988-95. 2004
  9. ncbi When prognosis precedes diagnosis: putting the cart before the horse
    Marc S Sabatine
    TIMI [Thrombolysis in Myocardial Infarction] Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Mass, USA
    CMAJ 172:1697-8. 2005
  10. ncbi Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 352:1179-89. 2005

Research Grants

  1. Genetic Predictors of Outcome in Acute MI
    Marc Sabatine; Fiscal Year: 2005
  2. Novel Biomarkers to Identify Vulnerable Patients with Coronary Artery Disease
    Marc Sabatine; Fiscal Year: 2009
  3. Novel Biomarkers to Identify Vulnerable Patients with Coronary Artery Disease
    Marc S Sabatine; Fiscal Year: 2010
  4. Antiplatelet Therapy: Platelet Inhibition, Polymorphisms, and Protein Biomarkers
    Marc S Sabatine; Fiscal Year: 2010

Collaborators

Detail Information

Publications97

  1. ncbi Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials)
    Emmanouil S Brilakis
    Cardiovascular Division, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Am J Cardiol 102:552-8. 2008
    ..In conclusion, compared with patients with ACS without previous CABG, those with previous CABG have a higher risk for adverse cardiac events and may derive similar benefit from intensive statin therapy...
  2. ncbi Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial
    Marc S Sabatine
    TIMI Study Group, Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Lancet 374:787-95. 2009
    ..Otamixaban is an intravenous direct factor Xa inhibitor. We aimed to assess its efficacy and safety in non-ST-elevation acute coronary syndromes and to identify the optimum dose range for further assessment in a phase 3 study...
  3. ncbi Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Circulation 105:1760-3. 2002
    ..Little is known, however, about the utility of these biomarkers in combination...
  4. ncbi Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 35
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Eur Heart J 30:162-9. 2009
    ..To determine whether an ultrasensitive assay can permit quantification of changes in circulating cardiac troponin (Tn) in the setting of stress test-induced myocardial ischaemia...
  5. ncbi Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial
    Marc S Sabatine
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Circulation 112:3846-54. 2005
    ..Whether these advantages translate into greater infarct-related artery patency and fewer adverse clinical events in patients with ST-elevation myocardial infarction (STEMI) receiving fibrinolytic therapy remains under study...
  6. ncbi Something old, something new: beta blockers and clopidogrel in acute myocardial infarction
    Marc S Sabatine
    Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA
    Lancet 366:1587-9. 2005
  7. ncbi Novel antiplatelet strategies in acute coronary syndromes
    Marc S Sabatine
    Cardiovascular Medicine Division, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Cleve Clin J Med 76:S8-15. 2009
    ..These include AZD6140, a reversible ADP receptor blocker; cangrelor, a rapidly acting intravenous ADP receptor blocker; and the thrombin receptor antagonist SCH 530348...
  8. ncbi Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 44:1988-95. 2004
    ..The aim of this study was to determine the effect of transient myocardial ischemia on circulating natriuretic peptide levels...
  9. ncbi When prognosis precedes diagnosis: putting the cart before the horse
    Marc S Sabatine
    TIMI [Thrombolysis in Myocardial Infarction] Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Mass, USA
    CMAJ 172:1697-8. 2005
  10. ncbi Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 352:1179-89. 2005
    ....
  11. ncbi Influence of race on death and ischemic complications in patients with non-ST-elevation acute coronary syndromes despite modern, protocol-guided treatment
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Mass 02115
    Circulation 111:1217-24. 2005
    ..Whether the disparate outcomes exist independently of potential biases in treatment patterns remains unclear...
  12. ncbi Association of hemoglobin levels with clinical outcomes in acute coronary syndromes
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Circulation 111:2042-9. 2005
    ..In the setting of an acute coronary syndrome (ACS), anemia has the potential to worsen myocardial ischemia; however, data relating anemia to clinical outcomes in ACS remain limited...
  13. ncbi Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 149:227-33. 2005
    ..We hypothesize that the addition of clopidogrel to standard fibrinolytic therapy in patients with acute STEMI will improve reperfusion...
  14. ncbi Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and th
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 109:874-80. 2004
    ..We sought to examine the effect of these advances on clinical outcomes and the benefits of an early invasive strategy in UA/NSTEMI...
  15. ncbi Combination of quantitative ST deviation and troponin elevation provides independent prognostic and therapeutic information in unstable angina and non-ST-elevation myocardial infarction
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 151:25-31. 2006
    ..We hypothesized that a combination of the two would offer complementary information regarding the benefit of an invasive strategy...
  16. ncbi Images in cardiovascular medicine. Fibrillary/immunotactoid glomerulopathy with cardiac involvement
    Marc S Sabatine
    Division of Cardiology, Massachusetts General Hospital and Harvard Medical School, Boston, Mass 02114, USA
    Circulation 105:e120-1. 2002
  17. ncbi Identification of patients at high risk for death and cardiac ischemic events after hospital discharge
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Am Heart J 143:966-70. 2002
    ..Patients with unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI) remain at risk for death and cardiac ischemic events after being discharged from the hospital...
  18. ncbi Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease
    Marc S Sabatine
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 115:1528-36. 2007
    ....
  19. ncbi Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease
    Marc S Sabatine
    Cardiovascular Division, Brigham and Women s Hospital and Department of Medicine, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Arterioscler Thromb Vasc Biol 27:2463-9. 2007
    ....
  20. ncbi Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservati
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    J Am Coll Cardiol 40:1761-8. 2002
    ....
  21. ncbi The management of unstable angina and non-ST-segment elevation myocardial infartion
    A A Chen
    Cardiology Division, Massachusetts General Hospital, Boston, MA 02115, USA
    Minerva Cardioangiol 51:433-45. 2003
    ....
  22. ncbi Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 117:1936-44. 2008
    ....
  23. ncbi The thrombolysis in myocardial infarction risk score in unstable angina/non-ST-segment elevation myocardial infarction
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 41:89S-95S. 2003
    ..In addition, using the risk score to categorize patients also effectively defines a gradient for benefit with specific treatments such as low-molecular-weight heparins, glycoprotein IIb/IIIa inhibitors, and an early invasive strategy...
  24. ncbi Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use
    Marc S Sabatine
    Cardiovascular Division, Department of Medicine, Thrombolysis in Myocardial Infarction Study Group, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 155:910-7. 2008
    ..However, the need for clopidogrel pretreatment is debated in patients receiving a glycoprotein IIb/IIIa inhibitor (GPI)...
  25. ncbi Cardiovascular genomics
    Marc S Sabatine
    Cardiovascular Division, Brigham and Women's Hospital, Boston, MA 02115, USA
    Circulation 113:e450-5. 2006
  26. ncbi Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 350 Longwood Ave, Boston, MA 02115, USA
    Circulation 125:233-40. 2012
    ..Circulating biomarkers can offer insight into subclinical cardiovascular stress and thus have the potential to aid in risk stratification and tailoring of therapy...
  27. ncbi Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study
    Marc S Sabatine
    The Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Mass 02115, USA
    JAMA 294:1224-32. 2005
    ..The benefit of clopidogrel pretreatment before percutaneous coronary intervention (PCI) remains debated and its use has not been universally adopted...
  28. ncbi Updated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) ST-segment elevation myocardial infarction critical pathway toolkit
    Christopher P Cannon
    TIMI Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    Crit Pathw Cardiol 7:223-31. 2008
    ..The updated STEMI tools are available to clinicians online on the STRIVE Website...
  29. ncbi Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarct
    C Michael Gibson
    TIMI Study Group and Cardiovascular Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 155:133-9. 2008
    ..We sought to evaluate the effect of nonemergent PCI on mortality among patients with STEMI treated with fibrinolytic administration and the consequence of clopidogrel pretreatment on this effect...
  30. ncbi Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction
    James R Harkness
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 159:55-62. 2010
    ..We sought to determine whether STRes provides incremental risk stratification to the TIMI risk score...
  31. ncbi Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction
    Masahisa Shimpo
    Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass, USA
    Circulation 109:2186-90. 2004
    ..These data suggest that ST2 may be a useful biomarker and that this novel inflammatory receptor may play a role in cardiac pathophysiology...
  32. ncbi The prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. Results from the TIMI 11B and TACTICS-TIMI 18 studies
    James A de Lemos
    Thrombolysis in Myocardial Infarction TIMI Study Group, Reynolds Cardiovascular Clinical Research Center, University of Texas Southwestern Medical School, 5323 Harry Hines Boulevard, Dallas, TX 75390 9047, USA
    J Am Coll Cardiol 40:238-44. 2002
    ..The goal of this study was to define the prognostic value of serum myoglobin in patients with non-ST-elevation acute coronary syndromes (ACS)...
  33. ncbi Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial
    David A Morrow
    Thrombolysis in Myocardial Infarction Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 155:49-55. 2008
    ..Elevated concentrations of MRP-8/14 are associated with a higher risk for future cardiovascular events in apparently healthy individuals but have not been assessed with respect to prognosis in patients with acute coronary syndrome...
  34. ncbi Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes
    James A de Lemos
    TIMI Study Group, Donald W Reynolds Cardiovascular Clinical Research Center, The University of Texas, Southwestern Medical School, Dallas, TX 75390 9047, USA
    Circulation 107:690-5. 2003
    ..MCP-1 appears to play a critical role at multiple stages in atherosclerosis, including the initiation of the fatty streak, promotion of plaque instability, and remodeling after myocardial infarction...
  35. ncbi Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes
    James A de Lemos
    Cardiovascular Division, Brigham and Women's Hospital, 350 Longwood Ave, First Floor, Boston, Mass 02115, USA
    Circulation 114:550-7. 2006
    ....
  36. ncbi Interactions between age, outcome of acute coronary syndromes, and tirofiban therapy
    James L Januzzi
    Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts, USA
    Am J Cardiol 91:457-61. 2003
  37. ncbi Association of impaired thrombolysis in myocardial infarction myocardial perfusion grade with ventricular tachycardia and ventricular fibrillation following fibrinolytic therapy for ST-segment elevation myocardial infarction
    C Michael Gibson
    TIMI Study Group, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 51:546-51. 2008
    ..The goal of this analysis was to evaluate the association of impaired Thrombolysis In Myocardial Infarction myocardial perfusion grade (TMPG) with sustained ventricular tachycardia (VT) or ventricular fibrillation (VF)...
  38. ncbi Sudden cardiac death in patients with stable coronary artery disease and preserved left ventricular systolic function
    Judith Hsia
    Department of Medicine, George Washington University, Washington, DC, USA
    Am J Cardiol 101:457-61. 2008
    ..Thus, among patients with stable CAD with preserved left ventricular systolic function receiving current standard-of-care including coronary revascularization, clinical characteristics can identify individuals at higher risk for SCD...
  39. ncbi Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction)
    David A Morrow
    Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
    Circulation 113:1745-52. 2006
    ..At 30 days, Lp-PLA2 activity is significantly lowered with high-dose statin therapy and is associated with an increased risk of CV events independent of C-reactive protein and LDL cholesterol levels...
  40. ncbi B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy
    Jessica L Mega
    TIMI Study Group, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 44:335-9. 2004
    ..These data support the value of combining markers of hemodynamic stress with traditional approaches to risk assessment in acute myocardial infarction...
  41. ncbi Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms
    Jessica L Mega
    TIMI Study Group, Brigham and Women's Hospital, Boston, Mass 02115, USA
    Am Heart J 149:846-50. 2005
    ..These findings likely explain in part the particular benefit of potent antithrombin and antiplatelet agents among patients with higher risk scores...
  42. ncbi Angiographic perfusion score in patients treated with PCI at late angiography following fibrinolytic administration for ST-segment elevation myocardial infarction is associated with morbidity and mortality at 30 days
    Yuri B Pride
    Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    J Thromb Thrombolysis 26:106-12. 2008
    ..In STEMI patients treated with fibrinolytic therapy and scheduled for angiography later during hospital admission, however, the association of later indices of flow and perfusion with clinical outcomes has not been assessed...
  43. ncbi Prospective evaluation of the prognostic implications of improved assay performance with a sensitive assay for cardiac troponin I
    Marc Bonaca
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 55:2118-24. 2010
    ..The purpose of this study was to investigate the prognostic implications of low-level increases in cardiac troponin I (cTnI) using a current-generation sensitive assay in patients with suspected acute coronary syndrome (ACS)...
  44. ncbi Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel
    Marc S Sabatine
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 49:2256-63. 2007
    ....
  45. ncbi Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, 75 Francis St, Boston, Massachusetts 02115, USA
    Circulation 114:26-31. 2006
    ..In the post-myocardial infarction setting, angiotensin-converting enzyme (ACE) inhibitors have been shown to be as effective in patients with impaired renal function as in those with preserved renal function...
  46. ncbi Angiographically evident thrombus following fibrinolytic therapy is associated with impaired myocardial perfusion in STEMI: a CLARITY-TIMI 28 substudy
    Ajay J Kirtane
    Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Eur Heart J 27:2040-5. 2006
    ..This finding emphasizes the roles of platelet aggregation and distal embolization in the pathogenesis of microvascular dysfunction in STEMI...
  47. ncbi Time for contrast material to traverse the epicardial artery and the myocardium in ST-segment elevation acute myocardial infarction versus unstable angina pectoris/non-ST-elevation acute myocardial infarction
    Graham C Wong
    TIMI Study Group and the Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 91:1163-7. 2003
    ..These data provide insight into potential mechanistic differences between these 2 clinical syndromes...
  48. ncbi Early dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: analysis from CLopidogrel as Adjunctive ReperfusIon TherapY (CLAR
    Matthew W Sherwood
    TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 159:964-971.e1. 2010
    ..The incremental prognostic use of the initial magnitude of troponin elevation and its value in conjunction with ST-segment resolution (STRes) in ST elevation myocardial infarction (STEMI) is less well defined...
  49. ncbi Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction
    Susan Cheng
    Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Circulation 119:1195-202. 2009
    ..Although weight-based nomograms have improved the efficacy and safety of dosing unfractionated heparin in ST-segment elevation myocardial infarction, achieving therapeutic anticoagulation in practice remains challenging...
  50. ncbi Updated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) unstable angina/non-ST elevation myocardial infarction critical pathway toolkit
    Christopher P Cannon
    TIMI Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    Crit Pathw Cardiol 7:43-81. 2008
    ..These materials are being made available online to help physicians, nurses, and hospitals implement the new guidelines and thus improve the quality of care and outcomes for patients with ACS...
  51. ncbi Relation between myocardial infarct size and ventricular tachyarrhythmia among patients with preserved left ventricular ejection fraction following fibrinolytic therapy for ST-segment elevation myocardial infarction
    Yuri B Pride
    Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 104:475-9. 2009
    ....
  52. ncbi Association of blood glucose with angiographic and clinical outcomes among patients with ST-segment elevation myocardial infarction (from the CLARITY-TIMI-28 study)
    Duane S Pinto
    Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 101:303-7. 2008
    ..IRA patency after fibrinolytic administration is related to admission glucose independent of clopidogrel administration...
  53. ncbi Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28
    Dalton S McLean
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Thromb Thrombolysis 24:85-91. 2007
    ..03). In conclusion, early clopidogrel treatment among CLARITY-TIMI 28 patients undergoing CABG was not associated with an increase in the rate of peri-operative bleeding and showed a trend toward reduction in 30-day ischemic events...
  54. ncbi Integration of proteomic-based tools for improved biomarkers of myocardial injury
    Robert E Gerszten
    Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Charlestown, MA 02129, USA
    Clin Chem 56:194-201. 2010
    ....
  55. ncbi Interaction between cigarette smoking and clinical benefit of clopidogrel
    Nihar R Desai
    Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Am Coll Cardiol 53:1273-8. 2009
    ..The aim of this study was to examine the interaction between cigarette smoking and the clinical efficacy of clopidogrel in ST-segment elevation myocardial infarction (STEMI)...
  56. ncbi Metabolomic identification of novel biomarkers of myocardial ischemia
    Marc S Sabatine
    Cardiovascular Division, Brigham and Women's Hospital, Donald W. Reynolds Cardiovascular Clinical Research Center on Atherosclerosis, Harvard Medical School, Boston, Massachusetts, USA
    Circulation 112:3868-75. 2005
    ....
  57. ncbi Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease
    David A Morrow
    Cardiovascular Division and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass 2115, USA
    JAMA 294:2866-71. 2005
    ..Clinical Trials Registration ClinicalTrials.gov Identifier: NCT00251576...
  58. ncbi Usefulness of clopidogrel in abolishing the increased risk of reinfarction associated with higher platelet counts in patients with ST-elevation myocardial infarction (results from CLARITY-TIMI 28)
    C Michael Gibson
    TIMI Study Group, Boston, Massachusetts, USA
    Am J Cardiol 98:761-3. 2006
    ..Clopidogrel therapy abolishes this increase in the risk of reinfarction as platelet counts increase. These data are consistent with a putative role of platelets in reinfarction...
  59. ncbi Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion
    Robert P Giugliano
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 350 Longwood Avenue, 1st Floor Offices, Boston, MA 02115, USA
    Am J Cardiol 93:1362-7, A5-6. 2004
    ..This new end point is proposed to evaluate the success of reperfusion therapy in patients who undergo early angiography...
  60. ncbi Predicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies
    James L Januzzi
    Cardiology Division, Massachusetts General Hospital, Boston, MA 02114, USA
    Am Heart J 151:360-6. 2006
    ..Troponin testing is useful for evaluating patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS); however, a significant percentage of patients are troponin negative at presentation and develop late rise of the marker...
  61. ncbi Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18
    David A Morrow
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 41:1264-72. 2003
    ....
  62. ncbi Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial
    David A Morrow
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, Massachusetts 02115, USA
    Circulation 114:281-8. 2006
    ..Retrospective analyses suggest that this risk may be modified with statin therapy. However, a role for hsCRP in monitoring the success of therapy remains uncertain...
  63. ncbi Thrombus precursor protein and clinical outcomes in patients with acute coronary syndromes
    Jessica L Mega
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 51:2422-9. 2008
    ..We sought to test the prognostic performance of thrombus precursor protein (TpP) in patients presenting with an acute coronary syndrome (ACS)...
  64. ncbi Cytochrome p-450 polymorphisms and response to clopidogrel
    Jessica L Mega
    Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 360:354-62. 2009
    ..Clopidogrel requires transformation into an active metabolite by cytochrome P-450 (CYP) enzymes for its antiplatelet effect. The genes encoding CYP enzymes are polymorphic, with common alleles conferring reduced function...
  65. ncbi A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 350 Longwood Avenue, First Floor, Boston, MA 02115, USA
    Eur Heart J 28:2070-6. 2007
    ..To determine the relationship between a strategy of enoxaparin (ENOX), early ST-segment resolution (STRes), and clinical outcomes on patients with ST-segment elevation myocardial infarction (STEMI) after fibrinolysis...
  66. ncbi Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis
    Jessica L Mega
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    JAMA 304:1821-30. 2010
    ..Data suggest its pharmacologic effect varies based on CYP2C19 genotype, but there is uncertainty regarding the clinical risk imparted by specific genotypes...
  67. ncbi Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 47:2326-31. 2006
    ..We aimed to determine whether intensive statin therapy reduces hospitalization for heart failure (HF) in high-risk patients...
  68. ncbi Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease (from the JUMBO-TIMI 26 trial)
    Marc P Bonaca
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Am J Cardiol 99:344-8. 2007
    ..This finding supports the physiologic relevance of procedural MI and the continued effort to define therapies that decrease the risk of this complication...
  69. ncbi Minimal ST-segment deviation: a simple, noninvasive method for identifying patients with a patent infarction-related artery after fibrinolytic administration
    Howard A Cooper
    Cardiovascular Division, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Am Heart J 144:790-5. 2002
    ..The sum of ST-segment resolution (sum-STRES) has a high positive predictive value (PPV) for a patent IRA, but is quite time-consuming...
  70. ncbi The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Pla
    Michelle O'Donoghue
    TIMI Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Am Coll Cardiol 54:678-85. 2009
    ..We evaluated the efficacy and safety of prasugrel and clopidogrel in the setting of a glycoprotein (GP) IIb/IIIa inhibitor...
  71. ncbi Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS)
    David A Morrow
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Am J Cardiol 94:774-6. 2004
    ..8% vs 21.9%; odds ratio [OR] 0.69, p = 0.04). This benefit was similar in magnitude as that for patients who underwent PCI (32.4% vs 22.2%; OR 0.60, p = 0.06). No benefit was evident in low-risk patients...
  72. ncbi B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thr
    David A Morrow
    Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 55:1189-96. 2010
    ..We designed a prospective evaluation of the interaction between B-type natriuretic peptide (BNP) and the effect of ranolazine in patients with acute coronary syndromes (ACS) as part of a randomized, blinded, placebo-controlled trial...
  73. ncbi Identification of genetic variants associated with response to statin therapy
    Jessica L Mega
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Arterioscler Thromb Vasc Biol 29:1310-5. 2009
    ..The purpose of this study was to test the association between polymorphisms in genes involved in either LDL cholesterol (LDL-C) metabolism or statin pharmacokinetics and LDL-C reduction with statins...
  74. ncbi Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes
    Jessica L Mega
    Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Circulation 119:2553-60. 2009
    ..The effect of CYP polymorphisms on the clinical outcomes in patients treated with prasugrel remains unknown...
  75. ncbi Metabolic signatures of exercise in human plasma
    Gregory D Lewis
    Cardiology Division and Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA 02114, USA
    Sci Transl Med 2:33ra37. 2010
    ..Plasma metabolic profiles obtained during exercise provide signatures of exercise performance and cardiovascular disease susceptibility, in addition to highlighting molecular pathways that may modulate the salutary effects of exercise...
  76. ncbi Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis
    Jessica L Mega
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Lancet 376:1312-9. 2010
    ..We also assessed the effect of genotype on the pharmacodynamic and pharmacokinetic properties of these drugs in healthy individuals...
  77. ncbi Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials
    Michelle L O'Donoghue
    TIMI Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    Lancet 374:989-97. 2009
    ..Conflicting data exist as to whether PPIs diminish the efficacy of clopidogrel. We assessed the association between PPI use, measures of platelet function, and clinical outcomes for patients treated with clopidogrel or prasugrel...
  78. ncbi Evaluation of the AccuTnI cardiac troponin I assay for risk assessment in acute coronary syndromes
    David A Morrow
    Department of Medicine and TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115, USA
    Clin Chem 49:1396-8. 2003
  79. ncbi Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Clin Chem 55:265-73. 2009
    ....
  80. ncbi Clinical application of C-reactive protein across the spectrum of acute coronary syndromes
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02461, USA
    Clin Chem 53:1800-7. 2007
    ..The ability to formulate recommendations regarding clinical use of hsCRP is limited by a paucity of data regarding several key issues. The purpose of this study was to evaluate hsCRP across the spectrum of ACS...
  81. ncbi Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Arterioscler Thromb Vasc Biol 28:562-7. 2008
    ..The purpose of this study was to investigate the association between the Ala227Pro polymorphism in the ADAMTS1 metalloproteinase gene and coronary heart disease and benefit from statin therapy in 2 independent cohorts...
  82. ncbi Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18
    David A Morrow
    TIMI Study Group Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Eur Heart J 29:1096-102. 2008
    ....
  83. ncbi Association between baseline neutrophil count, clopidogrel therapy, and clinical and angiographic outcomes in patients with ST-elevation myocardial infarction receiving fibrinolytic therapy
    Michelle O'Donoghue
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 350 Longwood Avenue, 1st Floor, Boston, MA 02115, USA
    Eur Heart J 29:984-91. 2008
    ..To investigate the association between neutrophil count, outcomes, and benefit of clopidogrel therapy in ST-elevation myocardial infarction (STEMI)...
  84. ncbi The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 48:37-42. 2006
    ..This study was designed to determine the relationship between clopidogrel and early ST-segment resolution (STRes) and the interaction of the two with clinical outcomes after fibrinolysis...
  85. ncbi Clopidogrel use in coronary artery disease
    Aaron L Baggish
    Department of Cardiology, Massachusetts General Hospital, Boston, MA, USA
    Expert Rev Cardiovasc Ther 4:7-15. 2006
    ..This review outlines the pharmacology of clopidogrel, highlights the results of clopidogrel trials in the setting of acute coronary syndromes, and presents areas of uncertainty and potential future work...
  86. ncbi Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis
    Michelle O'Donoghue
    TIMI Study Group, Brigham and Women s Hospital, 350 Longwood Ave, First Floor, Boston, MA 02115, USA
    JAMA 300:71-80. 2008
    ..Although an invasive strategy is frequently used in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS), data from some trials suggest that this strategy may not benefit women...
  87. ncbi Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombo
    Stephen D Wiviott
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, Mass 02115, USA
    Circulation 109:580-6. 2004
    ..We sought to examine the relationship between gender and cardiac biomarkers in patients with unstable angina (UA)/non-ST-segment elevation myocardial infarction (NSTEMI)...
  88. ncbi Challenges in translating plasma proteomics from bench to bedside: update from the NHLBI Clinical Proteomics Programs
    Robert E Gerszten
    Cardiology Division and Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA
    Am J Physiol Lung Cell Mol Physiol 295:L16-22. 2008
    ..Strategies to overcome these challenges are discussed...
  89. ncbi Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial
    Torbjørn Omland
    Department of Medicine, Akershus University Hospital, Lorenskog, Norway
    J Am Coll Cardiol 50:205-14. 2007
    ....
  90. ncbi Angiography and revascularization in patients with heart failure following fibrinolytic therapy for ST-elevation acute myocardial infarction
    Amir Kashani
    Rochester General Hospital, Rochester, New York, USA
    Am J Cardiol 95:228-33. 2005
    ....
  91. ncbi Prehospital fibrinolysis with dual antiplatelet therapy in ST-elevation acute myocardial infarction: a substudy of the randomized double blind CLARITY-TIMI 28 trial
    Freek W A Verheugt
    Department of Cardiology, 670 Cardiology, Heartcenter, University Medical Center St Radboud, 10 Geert Grooteplein Zuid, Nijmegen 6525, The Netherlands
    J Thromb Thrombolysis 23:173-9. 2007
    ..Intensified prehospital management of STEMI may shorten time to treatment and improve outcomes...
  92. ncbi Evaluation of the paraoxonases as candidate genes for stroke: Gln192Arg polymorphism in the paraoxonase 1 gene is associated with increased risk of stroke
    Koustubh Ranade
    Pharmaceutical Research Institute, Bristol Myers Squibb, Princeton, NJ 08543 5400, USA
    Stroke 36:2346-50. 2005
    ..We evaluated, in a comprehensive way, all 3 paraoxonase genes for association with stroke observed in the Cholesterol and Recurrent Events (CARE) trial...
  93. ncbi Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome
    Kausik K Ray
    Department of Public Health and Primary Care, University of Cambridge, Worts Causeway, Cambridge, CB1 8RN, United Kingdom
    Circulation 115:3071-8. 2007
    ..Neopterin is a soluble marker of monocyte activation, and elevated levels are of prognostic value in patients with stable coronary artery disease...
  94. ncbi Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials
    Olga A Iakoubova
    Celera, Inc, Alameda, California 94502, USA
    J Am Coll Cardiol 51:435-43. 2008
    ....
  95. ncbi Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study
    Olga A Iakoubova
    Celera, Alameda, California 9450, USA
    J Am Coll Cardiol 51:449-55. 2008
    ..We explored whether the benefit of intensive versus moderate statin therapy would be greater in carriers of KIF6 719Arg than in noncarriers...
  96. ncbi Asp92Asn polymorphism in the myeloid IgA Fc receptor is associated with myocardial infarction in two disparate populations: CARE and WOSCOPS
    Olga A Iakoubova
    Celera Inc, 1401 Harbor Bay Parkway, Alameda, CA 94502, USA
    Arterioscler Thromb Vasc Biol 26:2763-8. 2006
    ..Because the myeloid IgA Fc receptor encoded by FCAR mediates inflammation, we hypothesized that the FCAR Asp92Asn polymorphism is associated with risk of MI and that this risk would be modified by pravastatin...
  97. ncbi Diagnostic and prognostic utility of brain natriuretic Peptide in subjects admitted to the ICU with hypoxic respiratory failure due to noncardiogenic and cardiogenic pulmonary edema
    Dimitri Karmpaliotis
    Cardiology of Georgia, Piedmont Hospital, Fuqua Heart Center, 95 Collier Rd NW, Suite 2075, Atlanta, GA 30309, USA
    Chest 131:964-71. 2007
    ..We prospectively tested the utility of BNP for discriminating ARDS vs cardiogenic pulmonary edema (CPE)...

Research Grants8

  1. Genetic Predictors of Outcome in Acute MI
    Marc Sabatine; Fiscal Year: 2005
    ..Genomic control will be employed to detect and control for population stratification. Interaction terms will be incorporated into regression models to explore gene-environment and pharmacogenomic interactions. ..
  2. Novel Biomarkers to Identify Vulnerable Patients with Coronary Artery Disease
    Marc Sabatine; Fiscal Year: 2009
    ..Our goal is to evaluate potential new blood tests that may predict recurrent heart disease and determine which ones offer the greatest value. ..
  3. Novel Biomarkers to Identify Vulnerable Patients with Coronary Artery Disease
    Marc S Sabatine; Fiscal Year: 2010
    ..Our goal is to evaluate potential new blood tests that may predict recurrent heart disease and determine which ones offer the greatest value. ..
  4. Antiplatelet Therapy: Platelet Inhibition, Polymorphisms, and Protein Biomarkers
    Marc S Sabatine; Fiscal Year: 2010
    ....